Literature DB >> 3093129

Poor correlation between single-dose data and steady-state kinetics for phenobarbitone, primidone, carbamazepine and sodium valproate in children during monotherapy. Possible reasons for the lack of correlation.

J A Armijo, J L Herranz, R Arteaga, R Valiente.   

Abstract

An investigation was performed to determine the relationship between the serum drug concentration/dose ratio at 24 hours following a first dose and that at steady-state for phenobarbitone, primidone (as phenobarbitone and as primidone), carbamazepine and sodium valproate, in order to assess the utility of this method in clinical practice. The drugs were given as monotherapy to 63 children for the treatment of epilepsy or febrile convulsions. The correlation between concentration/dose ratios, instead of between serum concentrations, was investigated with the aim of allowing the use of variable doses. The correlation coefficients were: r = 0.30 for phenobarbitone; r = 0.05 for phenobarbitone derived from primidone; r = 0.38 for primidone; r = 0.19 for carbamazepine; and r = 0.52 for sodium valproate. None of these correlation coefficients differed statistically from 0. These low correlation coefficients contrast with the acceptable results found by other authors for other drugs, indicating that several factors may have a greater influence on this correlation than earlier investigations suggest. The poor correlation obtained emphasises the need for clinical verification of mathematical models based on theoretical considerations which do not always apply in practice.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3093129     DOI: 10.2165/00003088-198611040-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  47 in total

1.  DIPHENYLHYDANTOIN AND PHENOBARBITAL. SERUM LEVELS IN CHILDREN.

Authors:  O SVENSMARK; F BUCHTHAL
Journal:  Am J Dis Child       Date:  1964-07

2.  Quantitative estimation of diphenylhydantoin, primidone and phenobarbital in plasma by gas-liquid chromatography.

Authors:  H J Kupferberg
Journal:  Clin Chim Acta       Date:  1970-08       Impact factor: 3.786

3.  Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses.

Authors:  M Eichelbaum; K Ekbom; L Bertilsson; V A Ringberger; A Rane
Journal:  Eur J Clin Pharmacol       Date:  1975-06-13       Impact factor: 2.953

4.  [Serum phenobarbital levels in epileptics].

Authors:  P Loiseau; A Brachet; P Henry
Journal:  Encephale       Date:  1975       Impact factor: 1.291

5.  Gas-chromatographic analysis for valproic acid as phenacyl esters.

Authors:  R N Gupta; F Eng; M L Gupta
Journal:  Clin Chem       Date:  1979-07       Impact factor: 8.327

Review 6.  Drug dosage in renal disease.

Authors:  L Dettli
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

7.  The 24-hour serum digoxin level as a prognosticator of dosage requirement in low-birth-weight (LBW) infants.

Authors:  P K Ng; R L Collins-Nakai
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1983-10

8.  Single-dose kinetics predict steady-state concentrations on imipramine and desipramine.

Authors:  W Z Potter; A P Zavadil; I J Kopin; F K Goodwin
Journal:  Arch Gen Psychiatry       Date:  1980-03

9.  Plasma levels of primidone and its metabolite phenobarbital: effect of age and associated therapy.

Authors:  D Battino; G Avanzini; L Bossi; D Croci; C Cusi; C Gomeni; A Moise
Journal:  Ther Drug Monit       Date:  1983       Impact factor: 3.681

10.  Prediction of steady-state imipramine and desmethylimipramine plasma concentrations from single-dose data.

Authors:  D J Brunswick; J D Amsterdam; J Mendels; S L Stern
Journal:  Clin Pharmacol Ther       Date:  1979-05       Impact factor: 6.875

View more
  1 in total

Review 1.  Clinical pharmacokinetics of valproic acid--1988.

Authors:  G Zaccara; A Messori; F Moroni
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.